This clinical trial investigates heart failure with mildly reduced or preserved ejection fraction (a condition where the heart cannot pump blood effectively despite the heart’s main pumping chamber still being able to squeeze relatively normally) and systemic inflammation (widespread inflammation throughout the body). The study examines the effects of ziltivekimab compared to placebo when added to standard care. Ziltivekimab is administered under the skin once monthly for participants who have heart failure symptoms and elevated markers of inflammation in their blood.
The purpose of this research is to determine if ziltivekimab is better than placebo at improving heart failure symptoms and physical function in people with this specific type of heart failure who also have inflammation. The study focuses on participants with NYHA Class II-III heart failure (a classification system where Class II means mild symptoms during ordinary activities and Class III means marked limitation of activity due to symptoms) and specific levels of inflammation markers in their blood.
During the 12-month study, participants will receive either ziltivekimab or placebo while continuing their standard heart failure treatments. Their heart failure symptoms, quality of life, and physical function will be assessed using questionnaires and a six-minute walk test (a test measuring how far someone can walk in six minutes). Blood tests will also be performed to measure markers of heart failure and inflammation.
Bulgaria 
Czechia 
France 
Germany 
Greece 
Poland 
Spain 
